Sound Bioventures
Sound Bioventures is a venture capital fund that invests in about-to-be-clinical and clinical-stage private biotherapeutics companies in Europe, the UK and the USA. The firm focuses on supporting development of novel medicines that address significant unmet medical needs, with an emphasis on specialty therapeutics and orphan/rare disease opportunities. Fund I reached a first close at €110 million and the firm operates with a Scandinavian base and a transatlantic footprint.
Industries
Nr. of Employees
small (1-50)
Sound Bioventures
Sound Bioventures Management AB, Nordenskiöldsgatan 11a, 211 19 Malmö, Sweden. Visiting address: Sound Bioventures Management ApS c/o Ordnung, Strandvejen 125, DK-2900 Hellerup, Denmark.
Portfolio
Announced dosing of first cohort in Phase 1 study of ABO21009 for rheumatoid arthritis (May 2025).
#Biopharmaceuticals (immunomodulation / autoimmune)
Developing AX-158, a first-in-class oral Nck SH3.1 domain inhibitor for T cell-mediated diseases; participated in a $26M financing (May 2022).
#Biopharmaceuticals (T cell-mediated diseases; immunomodulation)
Launched from stealth after EUR 4 million seed financing led by Novo Holdings and Sound Bioventures (Nov 2022); in-licensed danegaptide as lead compound; aims to develop oral small molecules for DR and AMD.
#Ophthalmology (retinal vascular diseases: diabetic retinopathy, age-related macular degeneration)
Listed in Sound Bioventures portfolio navigation.
#Biopharmaceuticals / therapeutics (renal indications)
Announced dosing of first cohort in Phase 1 study of ABO21009 for rheumatoid arthritis (May 2025).
#Biopharmaceuticals (immunomodulation / autoimmune)
Developing AX-158, a first-in-class oral Nck SH3.1 domain inhibitor for T cell-mediated diseases; participated in a $26M financing (May 2022).
#Biopharmaceuticals (T cell-mediated diseases; immunomodulation)
Launched from stealth after EUR 4 million seed financing led by Novo Holdings and Sound Bioventures (Nov 2022); in-licensed danegaptide as lead compound; aims to develop oral small molecules for DR and AMD.
#Ophthalmology (retinal vascular diseases: diabetic retinopathy, age-related macular degeneration)
Listed in Sound Bioventures portfolio navigation.
#Biopharmaceuticals / therapeutics (renal indications)